Boston scores R&D coup with Merck KGaA's new hub

While some of its pharma competition has been downsizing the R&D side of the business, Merck KGaA has been adding to its research division. The German pharma company has opened a new $65 million facility in Billerica, MA, which is now one of four main research hubs scattered around the globe. The new site is another coup for the Boston area, which has become a magnet for drug developers keen to tap the growing scientific expertise in the area. Report